METTL3 and non-small cell lung carcinoma: Comparing with monotherapy, a combination of STM2457 and PTX or CBP exhibited more potent in vitro and in vivo anti-tumor efficacy, indicating that targeting METTL3 enhances the sensitivity of NSCLC cells to anticancer agents such as PTX and CBP.